Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases
Sponsor: Unicancer
Phase: 2
Disease: Metastatic colorectal cancer
EU trial number: 2025-524215-36-00
Population: Adults with unresectable, measurable pMMR/MSS, BRAF wild-type metastatic colorectal cancer without active liver metastases, ECOG performance status 0–1, and prior first-line FOLFOX-based therapy or eligible FOLFIRINOX-based therapy.
Register Investigator Interest
Interested in offering this trial to suitable patients?